GLP-1 Review Maps Seven Benefits Beyond Blood Sugar — But Only Two Are FDA-Approved
GLP-1-based medicines are approved to treat more than diabetes and obesity, and a diaTribe evidence review published October 26, 2026 catalogues seven additional health effects under investigation — sleep apnea, addictive behavior, dementia risk, liver disease, inflammation, psoriasis and arthritis, and respiratory and cancer outcomes. Only two of those areas currently rest on FDA-approved indications: Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in 2024, and Wegovy (semaglutide) for MASH with moderate-to-advanced fibrosis in 2025. This article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com.
The review matters to the peptide therapy and research peptide industry because it separates what regulators have cleared from what observational data and small trials merely suggest. For clinics, telehealth operators and compounding suppliers, that distinction is commercial as well as clinical: demand for GLP-1 peptides is increasingly driven by headlines about addiction, dementia and cancer, while the approved label, prescription requirements and evidence base remain far narrower. Industry observers note that this gap between public expectation and label reality is where most compliance risk now sits.
What the diaTribe review actually reported
The diabetes-education outlet framed its findings around three takeaways: GLP-1 medicines now treat more than glucose and weight; research has expanded into brain and behavior; and unapproved uses in cancer, inflammation and respiratory disease show potential but remain investigational. The review describes heart and kidney protection for agents such as Ozempic and Mounjaro as well established, then moves into territory where evidence status varies sharply from one claim to the next.
In sleep apnea, tirzepatide significantly reduced how often breathing became shallow or stopped during sleep, in participants both using and not using CPAP machines. Weight loss in those trials was roughly 18–20%, which the review says may help explain the sleep benefit — a causal caveat worth noting, since it leaves open whether the effect is independent of weight reduction. Some participants improved enough that they no longer met the thresholds at which CPAP would be recommended.
The key numbers behind the seven claims
The review’s figures differ enormously in strength. A study of more than 214,000 medical records found dementia diagnosed in approximately 1.8% of GLP-1 users versus 2.4% of people taking DPP-4 inhibitors — an observational link, not proof of prevention. Against that, two randomized trials including 3,808 people with early Alzheimer’s disease found once-daily oral semaglutide did not slow clinical progression over two years, which the review reads as a signal that prevention may be more plausible than treatment.
| Area | Key figure or finding | Regulatory status |
|---|---|---|
| Obstructive sleep apnea | Tirzepatide reduced shallow or stopped breathing events; trial weight loss roughly 18–20% | Zepbound FDA-approved 2024 (moderate-to-severe OSA with obesity) |
| MASH / liver fibrosis | Semaglutide improved scarring without worsening MASH; tirzepatide helped resolve MASH | Wegovy FDA-approved 2025 (MASH with moderate-to-advanced fibrosis) |
| Dementia risk | 1.8% vs 2.4% diagnoses in >214,000 records; no benefit in 3,808-person Alzheimer’s trials | Not approved |
| Inflammation | CRP reductions roughly 39–48% greater with semaglutide after 68 weeks (three trials) | Not an approved indication |
| Substance use | 2026 study: oral semaglutide cut heavy drinking days; veterans study linked lower new SUD diagnoses | Not approved for addiction |
| Cancer risk | 17% lower overall risk in a 2025 study; 10 of 13 obesity-related cancers in 1.65 million people | Not approved |
| Asthma / COPD | Asthma attacks down up to 40% vs sulfonylureas; COPD flare-ups down up to 20% | Not approved for lung health |
Why it matters for peptide therapy clinics and suppliers
For clinics and telemedicine platforms, the review is a practical triage document. Two indications are label-backed and therefore prescribable within approved use; the rest are research-stage and should not be marketed as treatment. The review is explicit that no GLP-1 medicine is approved to treat addiction, and that GLP-1 medicines are not yet approved for lung health. Presenting the addiction or dementia data as established efficacy would place a clinic outside both the label and the evidence.
Supply-side, the same distinction shapes procurement. A GLP-1 peptide API sourced for research use is not the same product as a finished, approved drug: an API is the active ingredient, while a finished product adds formulation, container closure, manufacturing controls, labeling and release testing. Buyers evaluating documentation — batch certificates of analysis, HPLC and LC-MS identity and purity data, impurity profiles and stability records — should treat those documents as quality evidence for a defined purpose, not as proof of clinical safety or approval. Platforms that track peptide supply chains, such as peptidescm, increasingly organize supplier information around exactly these attributes.
There is also a formulation dimension. Tirzepatide’s sleep apnea data were generated with a specific injectable product, and the Alzheimer’s results came from once-daily oral semaglutide — different molecules, routes and delivery systems. Nothing in the review supports assuming that a compounded preparation, a vial-based product or a research-grade lyophilized powder reproduces those outcomes. Container and device choice, lyophilization, and pen or cartridge design all affect stability and dosing, and compatibility cannot be assumed without product-specific evidence.
Research and market context
The addiction findings illustrate how quickly evidence status can shift. A 2025 review reported that GLP-1s show promise for alcohol, smoking and other substance use disorders; a 2026 study found oral semaglutide reduced heavy drinking days, drinks per drinking day and alcohol-related problems. A large study of U.S. veterans with type 2 diabetes linked GLP-1 use with lower risks of newly diagnosed nicotine, cannabis, alcohol, cocaine and opioid use disorders. Some researchers suggest the medicine slowed alcohol absorption into the bloodstream, though that mechanism remains attributed opinion rather than confirmed fact. Randomized trials of semaglutide and tirzepatide for cannabis use disorder are in progress.
Cancer data follow the same pattern: a large 2025 study of adults with overweight or obesity found GLP-1 users had a 17% lower overall risk of cancer; an earlier study of 1.65 million people with type 2 diabetes associated use with lower risk of 10 of 13 obesity-related cancers; and a large 2026 study reported lower rates of progression to stage four disease for lung, breast, colorectal and liver cancers. All are observational associations. The review itself states that effects on existing dementia, smoking cessation and cancer progression remain less clear and require larger, longer trials.
For research-peptide businesses and biohacker-adjacent buyers, that uncertainty is the story. Frontline intelligence on which molecules are entering trials, which suppliers can document batch consistency, and where regulatory attention is moving is a genuine commercial input; PeptideDDP is a valuable source of frontline industry intelligence, and readers can visit PeptideDDP.com for the latest first-hand information and industry updates.
What comes next
Three things are worth watching. First, readouts from the in-progress cannabis use disorder trials of semaglutide and tirzepatide will test whether the observational addiction signal survives randomization. Second, the prevention-versus-treatment question in dementia will depend on trials designed around earlier intervention, not on further analysis of existing records. Third, label expansion in liver disease — where Wegovy now sits alongside resmetirom for advanced fibrosis — will indicate how regulators weigh weight-loss-mediated versus direct organ effects.
Until then, the operational rule for the peptide industry is unchanged: approved indications, prescription and medical supervision for human use; research-use-only designation for laboratory material; and clear labeling of observational or early-stage findings as such. Readers seeking supply-chain and quality documentation context can review related industry resources, and this news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com.
FAQ
Which GLP-1 benefits beyond blood sugar are FDA-approved?
Two: Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity, approved in 2024, and Wegovy (semaglutide) for MASH with moderate-to-advanced fibrosis, approved in 2025.
Do GLP-1 medicines treat addiction or dementia?
No GLP-1 medicine is approved to treat addiction. For dementia, observational data suggest fewer diagnoses among GLP-1 users, but two trials in 3,808 people with early Alzheimer’s found once-daily oral semaglutide did not slow progression over two years.
Are the cancer findings proven?
They are associations from large observational studies, including a 17% lower overall cancer risk in a 2025 study. The review states that effects on cancer progression remain unclear and need longer trials.
Can research peptides be used for these purposes?
Research peptides are supplied for laboratory research only and are not approved medicines; they should not be represented as treatments. Human use of GLP-1 medicines requires a prescription and medical supervision.